Horizon Pharma plc (HZNP) Shares are Up 11.7%

Horizon Pharma plc (HZNP) has been under a strong bear grip, hence the stock is down -13.77% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 11.11% in the past 1 week. The stock has risen by 11.7% in the past week indicating that the buyers are active at lower levels, but the stock is down -15.51% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.34% and the 50-Day Moving Average is 2.79%.The 200 Day SMA reached 6.94% Horizon Pharma plc is up 16.43% in the last 3-month period. Year-to-Date the stock performance stands at -11.03%.


Horizon Pharma plc (HZNP) : The consensus price target for Horizon Pharma plc (HZNP) is $33.71 for the short term with a standard deviation of $7.65. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $45, however, the pessimist price target for the company is $24.

For the current week, the company shares have a recommendation consensus of Buy. Horizon Pharma plc (NASDAQ:HZNP): stock was range-bound between the intraday low of $18.84 and the intraday high of $19.49 after having opened at $19.49 on Fridays session. The stock finally closed in the red at $19.49, a loss of -1.53%. The stock remained in the red for the whole trading day. The total traded volume was 4,516,104 shares. The stock failed to cross $19.49 in Fridays trading. The stocks closing price on Thursday was $19.28.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.